FDA Clears NRx Preservative-Free Injectable Ketamine

NRx Pharmaceuticals Inc. has secured U.S. Food and Drug Administration clearance for a preservative-free injectable ketamine product, according to Mychesco. The report was published from Wilmington, Delaware, and identifies NRx Pharmaceuticals Inc. as the company behind the product.

FDA clearance reported

Mychesco reports that the FDA has cleared NRx’s preservative-free injectable ketamine product. The product is described in the report as injectable and preservative-free.

The reported FDA action concerns a ketamine product from NRx Pharmaceuticals Inc. Mychesco also places the development in the context of a drug shortage.

For medical sales professionals, the report provides a regulatory and product-characteristic update involving injectable ketamine. The supplied report identifies the product’s preservative-free formulation as a central element of the announcement.

Hospital supply context

According to Mychesco, the clearance positions NRx to supply American hospitals. The publisher’s report links that potential hospital supply role to the ongoing drug-shortage context.

The report does not provide further details on hospital distribution, product availability, clinical use, or account-level supply arrangements. Sales teams discussing the development can distinguish the reported clearance from those additional topics.

Mychesco’s coverage centers on three reported elements: FDA clearance, a preservative-free injectable ketamine product, and the prospect of supply to American hospitals. Those points frame the update for professionals following pharmaceutical and biotech developments affecting hospital customers.

Key reported details

• Mychesco reports that NRx Pharmaceuticals Inc. secured FDA clearance.
• The cleared product is described as preservative-free injectable ketamine.
• Mychesco reports that the action positions NRx to supply American hospitals.
• The publisher places the development amid a drug shortage.

As with other regulatory developments, product discussions should remain aligned with current company and regulatory communications. Mychesco’s report provides the stated basis for this update.